Administration of a Sigma Receptor Agonist Delays MCAO-Induced Neurodegeneration and White Matter Injury

Many pharmacological treatments for stroke have afforded protection in rodent models but failed to show efficacy in clinical trials. This discrepancy may be due to the lack of long-term functional studies. Previously, delayed administration of the sigma receptor agonist 1,3-di-o-tolylguanidine (DTG)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Leonardo, Christopher C., Hall, Aaron A., Collier, Lisa A., Green, Suzanne M., Willing, Alison E., Pennypacker, Keith R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2885737/
https://ncbi.nlm.nih.gov/pubmed/20563232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12975-009-0005-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky